Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Synjardy price, strengths & recalls

Brand of empagliflozin / metformin (generic)

Pharmacies pay $168.53 for 30 tablets of Synjardy 5 mg / 500 mg tablet this week, and from $167.90 to $336.37 across its 8 priced strengths and forms. 1 recall is ongoing. Its official label last changed on August 27, 2026.

1 open recallBrand
Pharmacies pay$168.53for 30 tablets of 5 mg / 500 mg tablet-0.1% in 4 weeks
Fair cash price
$204.31
Strengths
8
Makers
1
Updated
Nov 11

Synjardy price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
5 mg / 1000 mg (24 hr) extended-release tablet Brand$5.61$168.27 / 30 tabletsNo change-44.4%
10 mg / 1000 mg (24 hr) extended-release tablet Brand$11.21$336.37 / 30 tablets-0.1%-44.4%
12.5 mg / 1000 mg (24 hr) extended-release tablet Brand$5.60$167.90 / 30 tabletsNo change-44.4%
25 mg / 1000 mg (24 hr) extended-release tablet Brand$11.19$335.70 / 30 tabletsNo change-44.4%
5 mg / 1000 mg tablet Brand$5.60$168.01 / 30 tabletsNo change-44.5%
5 mg / 500 mg tablet Brand$5.62$168.53 / 30 tablets-0.1%-44.3%
12.5 mg / 1000 mg tablet Brand$5.60$168.04 / 30 tabletsNo change-44.4%
12.5 mg / 500 mg tablet Brand$5.61$168.35 / 30 tabletsNo change-44.4%

The lowest cost per tablet is 12.5 mg / 1000 mg (24 hr) extended-release tablet at $5.60. Strengths aren't interchangeable - ask your pharmacist or prescriber before changing.

Synjardy vs generic empagliflozin / metformin

There is no generic version of Synjardy on the market yet. Its last listed patent or exclusivity runs to December 11, 2034 - generics often follow, though court cases and settlements can move the date either way.

GenericEmpagliflozin / metformin prices

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
1 ongoing recall5 recalls on record, latest Jul 8, 2026

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for synjardy? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedAugust 27, 2026
Version23 of 23
EffectiveAug 25, 2026
Read the label

These highlights do not include all the information needed to use SYNJARDY and SYNJARDY XR safely and effectively. See full prescribing information for SYNJARDY and SYNJARDY XR. SYNJARDY® (empagliflozin and metformin hydrochloride tablets), for oral use SYNJARDY® XR (empagliflozin and metformin hydrochloride extended-release tablets), for oral use Initial U.S. Approval: 2015

This drug has a boxed warning

WARNING: LACTIC ACIDOSIS

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see Warnings and Precautions (5.1)].

Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and Precautions (5.1)].

Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the full prescribing information [see Dosage and Administration (2.1), Contraindications (4), Warnings and Precautions (5.1), Drug Interactions (7), and Use in Specific Populations (8.6, 8.7)].

If metformin-associated lactic acidosis is suspected, immediately discontinue SYNJARDY or SYNJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see Warnings and Precautions (5.1)].

WARNING: LACTIC ACIDOSIS

See full prescribing information for complete boxed warning.

Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL. (5.1)

Risk factors include renal impairment, concomitant use of certain drugs, age ≥65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment, and mitochondrial diseases. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information. (5.1)

If lactic acidosis is suspected, discontinue SYNJARDY or SYNJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended. (5.1)

Recent major changes (as listed on the label)

Boxed Warning | 8/2026 |

Warnings and Precautions, Lactic Acidosis (5.1) | 8/2026 |

Warnings and Precautions, Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), and Genital Mycotic Infections (5.4) | 10/2025 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA208658 · Boehringer Ingelheim
First approved
December 9, 2016 (10 years ago)
Latest approved change
August 11, 2026
Approved label
PDF, Aug 18, 2026
Generic makers
None on the market
Last patent listed
December 11, 2034
Exclusivity ends
December 20, 2026

Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.

Synjardy questions

How much does synjardy cost without insurance?

Pharmacies pay about $168.53 for 30 tablets of synjardy 5 mg / 500 mg tablet ($5.62 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $204.31. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Synjardy?

Yes: empagliflozin / metformin. Compare empagliflozin / metformin prices.

Is synjardy in shortage?

No shortage is reported for synjardy right now. We check the national shortage list every day.

Has synjardy been recalled?

5 recalls on record, 1 ongoing. Recalls name specific lots - check yours.

When did the synjardy label last change?

The official label was last updated on August 27, 2026 (version 23). See what changed.

Talk about synjardy

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.